New HIV pill on track for FDA approval

Gilead Sciences’ four-in-one HIV pill has been given the thumbs up by an FDA advisory group. The US regulator is set to make a final decision on the Quad – a combination of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate – by the end of August 2012. The FDA’s Antiviral Drugs Advisory Committee voted 13 to 1 to approve it for the treatment of HIV-1 infection in treatment-naïve adults. For further details, see InPharma